Cetuximab Cisplatin and Radiotherapy in Women With Locally Advanced Cervical Carcinoma

  • participants needed
  • sponsor
    University of Virginia
Updated on 22 January 2022
cervical carcinoma
cervical disease
concurrent chemoradiation


The anti-tumor activity of cetuximab prior to chemoradiotherapy and the safety and tolerability of cetuximab with concurrent chemoradiation will be determined in women with locally advanced or metastatic cervical carcinoma.


- Women with Federation of Gynecology and Obstetrics (FIGO) Clinical Stage IB2-IVB carcinoma of the cervix - Baseline cervical biopsy, blood samples, and FDG-PET/computed tomography (CT) scan - Cetuximab 400 mg/m2 on day 1 followed by cetuximab 250 mg/m2 on days 8 and 15 - Repeat cervical biopsy and FDG-PET/CT scan following cetuximab monotherapy - Radiation and weekly cisplatin 40 mg/m2 and cetuximab 250 mg/2 for 6 weeks - Cetuximab 250 mg/m2 weekly for 12 weeks - Repeat cervical biopsy (if tumor present) and FDG-PET/CT scan after completion of therapy - Follow for tumor recurrence and survival

Condition Cancer of the Cervix
Treatment Cetuximab
Clinical Study IdentifierNCT00292955
SponsorUniversity of Virginia
Last Modified on22 January 2022

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note